\
&
Contact us
\
&
Contact us
Published on | 4 months ago
Programmes MSCAYesterday a joint statement ‘No directionality in MSCA’ was published. The statement opposes the proposed introduction of directionality in the draft of the MSCA Work Programme 2026–2027. The signatory organisations shared their concerns about the European Commission’s proposal to establish targeted calls aligned with the EU's political priorities and use top-down funding from other parts of Horizon Europe to fund projects in strategic fields.
The statement is available on the websites of the current 18 signatory organisations: European Federation of Academies of Sciences and Humanities ALLEA, Aurora Universities Network, Universities of Science and Technology in Europe CESAER, Association of European universities Coimbra Group, European Alliance for Social Sciences and Humanities EASSH, European Consortium of Innovative Universities ECIU, Alliance of independent European research institutes in the life sciences EU-LIFE, European University Association EUA, European Council of Doctoral Candidates and Junior Researchers Eurodoc, Initiative for Science Europe (ISE), League of European Research Universities LERU, Marie Curie Alumni Association MCAA, Polish Science Contact Agency PolSCA, SPARC Europe, The Guild of European Research-Intensive Universities, Network of Universities from the Capitals of Europe UNICA, and Young European Research Universities Network YERUN.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
